JMD Conference & Exhibition
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Originally published online as doi:10.2353/jmoldx.2008.080043 on June 13, 2008

Published online before print June 13, 2008
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jmoldx.2008.080043v1
10/4/308    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Iafrate, A. J.
Right arrow Articles by Louis, D. N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Iafrate, A. J.
Right arrow Articles by Louis, D. N.
Journal of Molecular Diagnostics 2008, Vol. 10, No. 4
Copyright © 2008 American Society for Investigative Pathology & Association for Molecular Pathology
DOI: 10.2353/jmoldx.2008.080043

Commentary

"MGMT for pt mgmt": Is Methylguanine-DNA Methyltransferase Testing Ready for Patient Management?

A. John Iafrate and David N. Louis

Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts

Abstract

This Commentary reports on a robust quantitative assay for the interpretation of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation assays that should facilitate the comparison and implementation of such assays across laboratories.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society for Investigative Pathology and the Association for Molecular Pathology.